Baxter Gets FDA Approval for Myxredlin Insulin
July 22 2019 - 9:49AM
Dow Jones News
By Chris Wack
Baxter International Inc. (BAX) said Monday the U.S. Food and
Drug Administration approved Myxredlin insulin for IV infusion.
The medication company said Myxredlin is indicated for use as a
short-acting human insulin to improve glycemic control in adults
and pediatric patients with diabetes mellitus.
Baxter said it expects Myxredlin to be available in the U.S.
before the end of 2019.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
July 22, 2019 09:34 ET (13:34 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Baxter (NYSE:BAX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Baxter (NYSE:BAX)
Historical Stock Chart
From Apr 2023 to Apr 2024
